Literature DB >> 8506550

Long-term survival after first-ever stroke: the Oxfordshire Community Stroke Project.

M S Dennis1, J P Burn, P A Sandercock, J M Bamford, D T Wade, C P Warlow.   

Abstract

BACKGROUND AND
PURPOSE: There have been relatively few community-based studies of long-term prognosis after acute stroke. This study aimed to provide precise estimates of the absolute and relative risks of dying in an unselected cohort of patients with a first-ever stroke.
METHODS: Six hundred seventy-five patients were registered by a community-based stroke register (the Oxfordshire Community Stroke Project) and prospectively followed up for up to 6.5 years. Their relative risk of death was calculated using age- and sex-specific mortality rates for Oxfordshire.
RESULTS: During the first 30 days, 129 (19%) patients died. Patients who survived at least 30 days after a first-ever stroke thereafter had an average annual risk of death of 9.1%, 2.3-fold the risk in people from the general population. Although the absolute (about 15%) and relative (about threefold) risks of death were highest in these 30-day survivors over the first year after the stroke, they were at increased risk of dying over the next few years (range of relative risk for individual years, 1.1-2.9). Predictably, older patients had a worse absolute survival but, relative to the general population, stroke also increased the relative risk of dying in younger patients. During the first 30 days stroke accounts for most deaths; after this time nonstroke cardiovascular disease becomes increasingly important and is the most common cause of death after the first year.
CONCLUSIONS: These data highlight the importance of long-term secondary prevention of vascular events in stroke patients, targeted as much at the cardiovascular as at the cerebrovascular circulation.

Entities:  

Mesh:

Year:  1993        PMID: 8506550     DOI: 10.1161/01.str.24.6.796

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  100 in total

1.  Intra-arterial thrombolysis.

Authors: 
Journal:  AJNR Am J Neuroradiol       Date:  2001-09       Impact factor: 3.825

2.  The prognostic factors that influence long-term survival in acute large cerebral infarction.

Authors:  Sung Yun Cho; Chang Wan Oh; Hee-Joon Bae; Moon-Ku Han; Hyun Park; Jae Seung Bang
Journal:  J Korean Neurosurg Soc       Date:  2011-02-28

3.  Immediate effects of upper thoracic spine manipulation on hypertensive individuals.

Authors:  John Ward; Ken Tyer; Jesse Coats; Gabbrielle Williams; Kristina Kulcak
Journal:  J Man Manip Ther       Date:  2015-02

4.  JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice.

Authors: 
Journal:  Heart       Date:  2005-12       Impact factor: 5.994

Review 5.  Alzheimer's silent partner: cerebral amyloid angiopathy.

Authors:  Tanya L Cupino; Matthew K Zabel
Journal:  Transl Stroke Res       Date:  2013-11-19       Impact factor: 6.829

Review 6.  Long term cost-of-illness in stroke: an international review.

Authors:  Krista A Payne; Krista F Huybrechts; J Jaime Caro; Traci J Craig Green; Wendy S Klittich
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

7.  Fibrin-targeted PET probes for the detection of thrombi.

Authors:  Katie L Ciesienski; Yan Yang; Ilknur Ay; Daniel B Chonde; Galen S Loving; Tyson A Rietz; Ciprian Catana; Peter Caravan
Journal:  Mol Pharm       Date:  2013-01-30       Impact factor: 4.939

8.  Predicting symptomatic intracerebral hemorrhage versus lacunar disease in patients with longstanding hypertension.

Authors:  Elisabeth B Marsh; Rebecca F Gottesman; Argye E Hillis; Joyce Maygers; Erin Lawrence; Rafael H Llinas
Journal:  Stroke       Date:  2014-05-08       Impact factor: 7.914

9.  Physician visits and 30-day hospital readmissions in patients receiving hemodialysis.

Authors:  Kevin F Erickson; Wolfgang C Winkelmayer; Glenn M Chertow; Jay Bhattacharya
Journal:  J Am Soc Nephrol       Date:  2014-05-08       Impact factor: 10.121

10.  Cost effectiveness of intensive lipid-lowering treatment for patients with congestive heart failure and coronary heart disease in the US.

Authors:  Virginia M Rosen; Douglas C A Taylor; Hemangi Parekh; Ankur Pandya; David Thompson; Andreas Kuznik; David D Waters; Michael Drummond; Milton C Weinstein
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.